{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:40Z","timestamp":1786982380371,"version":"build-2736575974"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Teva Canada"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12325-025-03274-9","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T03:51:07Z","timestamp":1752637867000},"page":"4188-4209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of TV-46000 and Second-Generation Long-Acting Injectable Antipsychotics for Schizophrenia: A Systematic Literature Review and Network Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"42","author":[{"given":"Kelli R.","family":"Franzenburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Suett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sergerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard C.","family":"Margolese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"3274_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Arlington, VA: American Psychiatric Association; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"3274_CR2","doi-asserted-by":"publisher","first-page":"15067","DOI":"10.1038\/nrdp.2015.67","volume":"1","author":"RS Kahn","year":"2015","unstructured":"Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"3274_CR3","first-page":"1","volume":"11","author":"JA Lieberman","year":"2006","unstructured":"Lieberman JA, Malaspina D, Jarskog LF. Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. CNS Spectr. 2006;11(4):1\u201313.","journal-title":"CNS Spectr"},{"issue":"5","key":"3274_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40263-021-00815-y","volume":"35","author":"D Lin","year":"2021","unstructured":"Lin D, Thompson-Leduc P, Ghelerter I, et al. Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States: a systematic review and meta-analysis. CNS Drugs. 2021;35(5):469\u201381.","journal-title":"CNS Drugs"},{"issue":"5","key":"3274_CR5","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1017\/S109285292100050X","volume":"27","author":"RS Patel","year":"2022","unstructured":"Patel RS, Tankersley WE. Real-world effectiveness of long-acting injectable antipsychotics to reduce 90-day and annual readmission in psychotic disorders: insights from a state psychiatric hospital. CNS Spectr. 2022;27(5):626\u201333.","journal-title":"CNS Spectr"},{"key":"3274_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1471-244X-13-50","volume":"13","author":"R Emsley","year":"2013","unstructured":"Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;13:50.","journal-title":"BMC Psychiatry"},{"issue":"suppl 3","key":"3274_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.15032su1","volume":"77","author":"CU Correll","year":"2016","unstructured":"Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1\u201324.","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"3274_CR8","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","volume":"74","author":"J Tiihonen","year":"2017","unstructured":"Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiat. 2017;74(7):686\u201393.","journal-title":"JAMA Psychiat"},{"key":"3274_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.schres.2018.07.020","volume":"202","author":"RE Nielsen","year":"2018","unstructured":"Nielsen RE, Hessellund KB, Valentin JB, Licht RW. Second-generation LAI are associated to favorable outcome in a cohort of incident patients diagnosed with schizophrenia. Schizophr Res. 2018;202:234\u201340.","journal-title":"Schizophr Res"},{"issue":"Suppl 14","key":"3274_CR10","first-page":"27","volume":"68","author":"JM Kane","year":"2007","unstructured":"Kane JM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry. 2007;68(Suppl 14):27\u201330.","journal-title":"J Clin Psychiatry"},{"key":"3274_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-244X-10-2","volume":"10","author":"H Ascher-Svanum","year":"2010","unstructured":"Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010;10:2.","journal-title":"BMC Psychiatry"},{"key":"3274_CR12","unstructured":"Uzedy [prescribing information]. Parsippany, NJ: Teva Neuroscience, Inc.; 2024."},{"issue":"12","key":"3274_CR13","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S2215-0366(23)00288-2","volume":"10","author":"JM Kane","year":"2023","unstructured":"Kane JM, Harary E, Eshet R, et al. Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria. Lancet Psychiatry. 2023;10(12):934\u201343.","journal-title":"Lancet Psychiatry"},{"key":"3274_CR14","unstructured":"Clinicaltrials.gov. A study to evaluate TV-46000 as maintenance treatment in adult and adolescent participants with schizophrenia (RISE). 2021. https:\/\/clinicaltrials.gov\/study\/NCT03503318. Accessed 1 September 2023."},{"issue":"8","key":"3274_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40263-024-01102-2","volume":"38","author":"JM Kane","year":"2024","unstructured":"Kane JM, Eshet R, Harary E, et al. A long-term safety and tolerability study of TV-46000 for subcutaneous use in adult and adolescent patients with schizophrenia: a phase 3, randomized, double-blinded clinical trial. CNS Drugs. 2024;38(8):625\u201336.","journal-title":"CNS Drugs"},{"key":"3274_CR16","unstructured":"Clinicaltrials.gov. A study to test if TV-46000 is safe for maintenance treatment of schizophrenia (SHINE). 2022. https:\/\/clinicaltrials.gov\/ct2\/study\/NCT03893825. Accessed 1 September 2023."},{"issue":"10327","key":"3274_CR17","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(21)01997-8","volume":"399","author":"J Schneider-Thoma","year":"2022","unstructured":"Schneider-Thoma J, Chalkou K, Dorries C, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet. 2022;399(10327):824\u201336.","journal-title":"Lancet"},{"issue":"10202","key":"3274_CR18","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939\u201351.","journal-title":"Lancet"},{"key":"3274_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008016.pub3","author":"A Ceraso","year":"2020","unstructured":"Ceraso A, Lin JJ, Schneider-Thoma J, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2020. https:\/\/doi.org\/10.1002\/14651858.CD008016.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"3274_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","volume":"8","author":"T Kishimoto","year":"2021","unstructured":"Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387\u2013404.","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"3274_CR21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/wps.20632","volume":"18","author":"T Kishimoto","year":"2019","unstructured":"Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry. 2019;18(2):208\u201324.","journal-title":"World Psychiatry"},{"issue":"11","key":"3274_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"issue":"2","key":"3274_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376.","journal-title":"Schizophr Bull"},{"issue":"5","key":"3274_CR24","first-page":"46","volume":"12","author":"J Lincoln","year":"2013","unstructured":"Lincoln J. Long-acting injectable aripiprazole for adult schizophrenia. Current Psychiatry. 2013;12(5):46\u20139.","journal-title":"Current Psychiatry"},{"issue":"5","key":"3274_CR25","doi-asserted-by":"publisher","first-page":"617","DOI":"10.4088\/JCP.11m07530","volume":"73","author":"JM Kane","year":"2012","unstructured":"Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73(5):617\u201324.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"3274_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004301","volume":"4","author":"C Cameron","year":"2014","unstructured":"Cameron C, Coyle D, Richter T, et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open. 2014;4(6):e004301.","journal-title":"BMJ Open"},{"key":"3274_CR27","unstructured":"National Institute for Health and Care Excellence (NICE). Single technology appraisal: user guide for company evidence submission template (Section 2.5 - Quality assessment of the relevant clinical effectiveness evidence). 2015. https:\/\/www.nice.org.uk\/process\/pmg24\/chapter\/clinical-effectiveness. Accessed 1 September 2023."},{"key":"3274_CR28","unstructured":"Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU technical support document 4: inconsistency in networks of evidence based on randomised controlled trials. 2011. https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds\/full-list. Accessed 1 September 2023."},{"issue":"2\u20133","key":"3274_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","volume":"116","author":"D Hough","year":"2010","unstructured":"Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2\u20133):107\u201317.","journal-title":"Schizophr Res"},{"issue":"7","key":"3274_CR30","doi-asserted-by":"publisher","first-page":"pyw018","DOI":"10.1093\/ijnp\/pyw018","volume":"19","author":"AJ Savitz","year":"2016","unstructured":"Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharmacol. 2016;19(7):pyw018. https:\/\/doi.org\/10.1093\/ijnp\/pyw018.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1\u20132","key":"3274_CR31","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.schres.2015.07.007","volume":"168","author":"D Naber","year":"2015","unstructured":"Naber D, Hansen K, Forray C, et al. QUALIFY: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 2015;168(1\u20132):498\u2013504.","journal-title":"Schizophr Res"},{"issue":"8","key":"3274_CR32","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jamapsychiatry.2015.0241","volume":"72","author":"J Berwaerts","year":"2015","unstructured":"Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs. placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiat. 2015;72(8):830\u20139.","journal-title":"JAMA Psychiat"},{"key":"3274_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.euroneuro.2024.03.003","volume":"83","author":"D Wang","year":"2024","unstructured":"Wang D, Schneider-Thoma J, Siafis S, et al. Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: systematic review and network meta-analysis. Eur Neuropsychopharmacol. 2024;83:11\u20138.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"3274_CR34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/wps.20972","volume":"21","author":"G Ostuzzi","year":"2022","unstructured":"Ostuzzi G, Bertolini F, Tedeschi F, et al. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry. 2022;21(2):295\u2013307.","journal-title":"World Psychiatry"},{"key":"3274_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.653916","volume":"12","author":"T Si","year":"2021","unstructured":"Si T, Shi C, Sun L, Zhang Y, Zhang L. Assessment of the minimum clinically important difference in symptoms and functions of patients with acute schizophrenia: a post hoc analysis of an open-label, single-arm multicenter study. Front Psychiatry. 2021;12:653916.","journal-title":"Front Psychiatry"},{"issue":"11","key":"3274_CR36","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","volume":"36","author":"I Usach","year":"2019","unstructured":"Usach I, Martinez R, Festini T, Peris JE. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36(11):2986\u201396.","journal-title":"Adv Ther"},{"key":"3274_CR37","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2147\/NDT.S407259","volume":"19","author":"M Zhao","year":"2023","unstructured":"Zhao M, Qin B, Mao Y, et al. Paliperidone palmitate versus risperidone long-acting injectable in patients with schizophrenia: a meta-analysis of efficacy and safety. Neuropsychiatr Dis Treat. 2023;19:749\u201357.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"3274_CR38","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40261-021-01000-1","volume":"41","author":"C Rognoni","year":"2021","unstructured":"Rognoni C, Bertolani A, Jommi C. Second-generation antipsychotic drugs for patients with schizophrenia: systematic literature review and meta-analysis of metabolic and cardiovascular side effects. Clin Drug Investig. 2021;41(4):303\u201319.","journal-title":"Clin Drug Investig"},{"key":"3274_CR39","doi-asserted-by":"publisher","unstructured":"Majer IM, Gaughran F, Sapin C, Beillat M, Treur M. Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials. J Mark Access Health Policy. 2015;3. https:\/\/doi.org\/10.3402\/jmahp.v3.27208.","DOI":"10.3402\/jmahp.v3.27208"},{"issue":"5","key":"3274_CR40","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1177\/0269881110372817","volume":"25","author":"S Gopal","year":"2011","unstructured":"Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol. 2011;25(5):685\u201397.","journal-title":"J Psychopharmacol"},{"issue":"8","key":"3274_CR41","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1185\/03007995.2011.595000","volume":"27","author":"CM Kozma","year":"2011","unstructured":"Kozma CM, Slaton T, Dirani R, Fastenau J, Gopal S, Hough D. Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE). Curr Med Res Opin. 2011;27(8):1603\u201311.","journal-title":"Curr Med Res Opin"},{"key":"3274_CR42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1471-244X-14-52","volume":"14","author":"JK Sliwa","year":"2014","unstructured":"Sliwa JK, Fu DJ, Bossie CA, Turkoz I, Alphs L. Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate. BMC Psychiatry. 2014;14:52.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"3274_CR43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1744-859X-12-22","volume":"12","author":"M Markowitz","year":"2013","unstructured":"Markowitz M, Fu DJ, Levitan B, Gopal S, Turkoz I, Alphs L. Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. Ann Gen Psychiatry. 2013;12(1):22.","journal-title":"Ann Gen Psychiatry"},{"issue":"4","key":"3274_CR44","first-page":"171","volume":"28","author":"WW Fleischhacker","year":"2013","unstructured":"Fleischhacker WW, Sanchez R, Johnson B, et al. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. Int Clin Psychopharmacol. 2013;28(4):171\u20136.","journal-title":"Int Clin Psychopharmacol"},{"key":"3274_CR45","unstructured":"Clinicaltrials.gov. Intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia (ASPIRE). 2008. https:\/\/clinicaltrials.gov\/study\/NCT00705783. Accessed 1 September 2023."},{"key":"3274_CR46","unstructured":"European Clinical Trials Register. A 52-week, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole (OPC-14597) as maintenance treatment in patients with schizophrenia. 2009. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-002675-27\/BG. Accessed 1 September 2023."},{"issue":"2","key":"3274_CR47","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3371\/CSRP.KASA.022015","volume":"9","author":"JM Kane","year":"2015","unstructured":"Kane JM, Sanchez R, Baker RA, et al. Patient-centered outcomes with aripiprazole once-monthly for maintenance treatment in patients with schizophrenia: results from two multicenter, randomized, double-blind studies. Clin Schizophr Relat Psychoses. 2015;9(2):79\u201387.","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"2\u20133","key":"3274_CR48","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.schres.2014.09.019","volume":"159","author":"WW Fleischhacker","year":"2014","unstructured":"Fleischhacker WW, Baker RA, Eramo A, et al. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies. Schizophr Res. 2014;159(2\u20133):415\u201320.","journal-title":"Schizophr Res"},{"key":"3274_CR49","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.schres.2017.04.013","volume":"192","author":"D Naber","year":"2018","unstructured":"Naber D, Baker RA, Eramo A, et al. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study. Schizophr Res. 2018;192:205\u201310.","journal-title":"Schizophr Res"},{"key":"3274_CR50","unstructured":"Clinicaltrials.gov. Aripiprazole once-monthly versus paliperidone palmitate in adult patients with schizophrenia. 2013. https:\/\/clinicaltrials.gov\/study\/NCT01795547. Accessed 1 September 2023."},{"key":"3274_CR51","unstructured":"European Clinical Trials Register. A 28-week, randomised, open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients with schizophrenia. 2013. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-002785-12\/SE. Accessed 1 September 2023."},{"key":"3274_CR52","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/eip.12685","volume":"13","author":"KS Bell Lynum","year":"2019","unstructured":"Bell Lynum KS, Turkoz I, Kim E. Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia. Early Interv Psychiatry. 2019;13:667\u201372.","journal-title":"Early Interv Psychiatry"},{"key":"3274_CR53","unstructured":"Clinicaltrials.gov. A study of paliperidone palmitate 3 month formulation for the treatment of patients with schizophrenia. 2012. https:\/\/www.clinicaltrials.gov\/study\/NCT01529515. Accessed 1 September 2023."},{"key":"3274_CR54","unstructured":"European Clinical Trials Register. A randomized, multicenter, double-blind, relapse prevention study of paliperidone palmitate 3 month formulation for the treatment of subjects with schizophrenia. 2011. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-004676-11\/RO. Accessed 1 September 2023."},{"issue":"6","key":"3274_CR55","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1590\/1516-4446-2018-0153","volume":"41","author":"AJ Savitz","year":"2019","unstructured":"Savitz AJ, Xu H, Gopal S, Nuamah I, Mathews M, Soares B. Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: a subgroup analysis of data from two large phase 3 randomized, double-blind studies. Braz J Psychiatry. 2019;41(6):499\u2013510.","journal-title":"Braz J Psychiatry"},{"issue":"6","key":"3274_CR56","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1080\/03007995.2017.1300144","volume":"33","author":"C Chirila","year":"2017","unstructured":"Chirila C, Nuamah I, Woodruff K. Health care resource use analysis of paliperidone palmitate 3 month injection from two phase 3 clinical trials. Curr Med Res Opin. 2017;33(6):1083\u201390.","journal-title":"Curr Med Res Opin"},{"key":"3274_CR57","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2147\/NDT.S226296","volume":"16","author":"S Gopal","year":"2020","unstructured":"Gopal S, Gogate J, Pungor K, Kim E, Singh A, Mathews M. Improvement of negative symptoms in schizophrenia with paliperidone palmitate 1-month and 3-month long-acting injectables: results from a phase 3 non-inferiority study. Neuropsychiatr Dis Treat. 2020;16:681\u201390.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"3274_CR58","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/ppc.12267","volume":"54","author":"J Kern Sliwa","year":"2018","unstructured":"Kern Sliwa J, Savitz A, Nuamah I, et al. An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate. Perspect Psychiatr Care. 2018;54(4):530\u20138.","journal-title":"Perspect Psychiatr Care"},{"issue":"8","key":"3274_CR59","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40261-018-0647-z","volume":"38","author":"M Mathews","year":"2018","unstructured":"Mathews M, Pei H, Savitz A, et al. Paliperidone palmitate 3-monthly versus 1-monthly Injectable in patients with schizophrenia with or without prior exposure to oral risperidone or paliperidone: a post hoc, subgroup analysis. Clin Drug Investig. 2018;38(8):695\u2013702.","journal-title":"Clin Drug Investig"},{"key":"3274_CR60","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/NDT.S189668","volume":"15","author":"AJ Savitz","year":"2019","unstructured":"Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population. Neuropsychiatr Dis Treat. 2019;15:587\u2013602.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"3274_CR61","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/YIC.0000000000000190","volume":"32","author":"AJ Savitz","year":"2017","unstructured":"Savitz AJ, Xu H, Gopal S, Nuamah I, Hough D, Mathews M. Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study. Int Clin Psychopharmacol. 2017;32(6):329\u201336.","journal-title":"Int Clin Psychopharmacol"},{"key":"3274_CR62","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.2147\/NDT.S134287","volume":"13","author":"AJ Savitz","year":"2017","unstructured":"Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study. Neuropsychiatr Dis Treat. 2017;13:2193\u2013207.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3274_CR63","unstructured":"Clinicaltrials.gov. Study of paliperidone palmitate 3 month and 1 month formulations for the treatment of patients with schizophrenia. 2012. https:\/\/clinicaltrials.gov\/study\/NCT01515423. Accessed 1 September 2023."},{"key":"3274_CR64","unstructured":"European Clinical Trials Register. A randomized, multicenter, double-blind, non-inferiority study of paliperidone palmitate 3 month and 1 month formulations for the treatment of subjects with schizophrenia. 2012. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-004889-15\/PT. Accessed 1 September 2023."},{"issue":"2","key":"3274_CR65","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1192\/bjp.bp.113.134213","volume":"205","author":"WW Fleischhacker","year":"2014","unstructured":"Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014;205(2):135\u201344.","journal-title":"Br J Psychiatry"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03274-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03274-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03274-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T11:51:59Z","timestamp":1757245919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03274-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":65,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3274"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03274-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kelli R. Franzenburg, Rolf Hansen, Mark Suett, Stephen F. Thompson, and Martin Sergerie are employees and shareholders of Teva Pharmaceuticals. David Garcia is an employee of EVERSANA, which provides commercialization services to the life sciences industry. Teva Pharmaceuticals contracted EVERSANA to complete this SLR and NMA. Howard C. Margolese received research grant support from AIFred, SyneuRx, and The Montreal General Hospital Foundation; speaker\/consultation\/ad board fees from AbbVie, Bausch Health, Boehringer Ingelheim, HLS Therapeutics, Lundbeck, Janssen, Newron, Otsuka, and Teva Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This article is licensed under a Creative Commons Attribution\u2014Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third-party material in this article are included in the article\u2019s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article\u2019s Creative. Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view.a copy of this license, visit\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Open Access"}}]}}